EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Amicus Therapeutics's enterprise value is $2,065.1 Mil.
Amicus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $528.3 Mil. Therefore, Amicus Therapeutics's EV-to-Revenue for today is 3.91.
The historical rank and industry rank for Amicus Therapeutics's EV-to-Revenue or its related term are showing as below:
FOLD'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.8 Med: 14.8 Max: 4964.07
Current: 3.8
During the past 13 years, the highest EV-to-Revenue of Amicus Therapeutics was 4964.07. The lowest was 3.80. And the median was 14.80.
FOLD's EV-to-Revenue is ranked better than 64.64% of 987
companies
in the Biotechnology industry
Industry Median: 6.76
vs FOLD: 3.80
The historical data trend for Amicus Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amicus Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Amicus Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amicus Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Amicus Therapeutics's EV-to-Revenue falls into.
Amicus Therapeutics's current Enterprise Value is $2,065.1 Mil.
Amicus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $528.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics's share price for today is $5.98.
Amicus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Amicus Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FOLD has been successfully added to your 